Egnach, May 5, 2025 – The recently published results of the Apple Hearing Study show an alarmingly high prevalence of tinnitus: Over 77% of participants reported having suffered from ear noises at some point in their lives. About 15% experience symptoms even daily. While Apple raises awareness of the societal relevance of the problem with its study, the therapeutic response remains exclusively with Resaphene Suisse AG and its patented medical product tinniwell.

tinniwell: Unique therapy instead of mere sound masking

“Apple has provided important data with the study – but no solution,” says Anke Rauterkus, CEO of Resaphene Suisse AG. “tinniwell is currently the only approved therapy device that not only masks tinnitus but treats the root cause – and in many cases heals.”

While Apple users are referred to simple sound masking, nature sounds, or mindfulness exercises, tinniwell takes a crucial step further: The device combines individually tailored music therapy with targeted heat stimulation of the auditory nerve – based on neurological research and with clinically documented effectiveness.

Patent protection ensures exclusivity

The innovative therapeutic approach of tinniwell is protected by international patents. This prevents other companies – including technology giants like Apple – from offering a comparable medical solution.

“Our technology is unique. Anyone who really wants to treat tinnitus cannot ignore tinniwell,” says Rauterkus. “We welcome that Apple is bringing visibility to the issue of tinnitus – but we have already developed the solution and made it available worldwide.”

Global demand is rising

Resaphene Suisse AG observes a significant increase in demand following the publication of the Apple data. More and more affected individuals are seeking real therapies instead of mere symptom treatment. tinniwell is CE certified, non-invasive, and already successfully used in several European countries. Market entries in the USA and Asia are in preparation.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015, which has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 71 510 07 24
a.rauterkus@resaphene.ch